Skip to content

Trial Summary

We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control.  If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally.



ACTRN/NCT /ethics:


Scientific title:

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeBowel
Trial TypeTreatment
PhasePhase III
Age Range18+ years
Tumour StreamBowel
Cancer StageAll stages
Anticipated Start Date2018-12-01
Anticipated End Date2026-01-06

Participating Hospitals

HospitalLyell McEwin Hospital
Clinical Trial CoordinatorAndy Phay
Phone08 8282 0833
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting